A Study Evaluating the Prevalence, Incidence and Predictors for Development of the Impulse Control Disorders in Patients with Prolactinomas Treated with Dopamine Agonist Therapy

Overview

About this study

The purpose of this study is to establish incidence and prevalence of Impulse Control Disorders (ICDs) in patients with prolactinomas treated with dopamine agonists (DA), to determine the predictors of ICD development, and to establish a predictor scoring system that could be subsequently validated and applied prior to initiation of DA.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Age 18 years old and above.
  • Diagnosis of prolactinoma.
  • Ability to provide informed consent.

Exclusion Criteria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Irina Bancos, M.D.

Open for enrollment

Contact information:

Melinda Thomas

(507)293-6628

Thomas.Melinda@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Irina Bancos, M.D.

Contact us for the latest status

Contact information:

Melinda Thomas

(507)293-6628

Thomas.Melinda@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20455834

Mayo Clinic Footer